Overview

RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

Status:
Completed
Trial end date:
2019-03-29
Target enrollment:
Participant gender:
Summary
This research study will test the safety of RAD001 in combination with temozolomide.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Massachusetts General Hospital
Novartis
Schering-Plough
Treatments:
Dacarbazine
Everolimus
Sirolimus
Temozolomide